ResearcherKyoto Prefectural University of MedicineNo recent work listed

Ryoichi Tanaka

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-6692-5776; OpenAlex author ID A5068961063. Sources: OpenAlex.

Their work

Papers: 2
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 2

Papers, trials and grants by year

2015: 1 paper · 2016: 1 paper

Papers 2

MEK Inhibitor Suppresses Expression of the miR-17-92 Cluster with G1-Phase Arrest in HT-29 Human Colon Cancer Cells and MIA PaCa-2 Pancreatic Cancer Cells. Co-author DOI 10.21873/anticanres.11001 ↗
Metformin Causes G1-Phase Arrest via Down-Regulation of MiR-221 and Enhances TRAIL Sensitivity through DR5 Up-Regulation in Pancreatic Cancer Cells. Co-author DOI 10.1371/journal.pone.0125779 ↗

Closest collaborators

The 2 strongest of 2 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Toshiyuki Sakai · 2 shared papers, 2015–2016 · strength 0.15
- Paper MEK Inhibitor Suppresses Expression of the miR-17-92 Cluster with G1-Phase Arrest in HT-29 Human Colon Cancer Cells and… DOI 10.21873/anticanres.11001 ↗
- Paper Metformin Causes G1-Phase Arrest via Down-Regulation of MiR-221 and Enhances TRAIL Sensitivity through DR5 Up-Regulatio… DOI 10.1371/journal.pone.0125779 ↗
Yoshihiro Sowa · 1 shared paper, 2016 · strength 0.08
- Paper MEK Inhibitor Suppresses Expression of the miR-17-92 Cluster with G1-Phase Arrest in HT-29 Human Colon Cancer Cells and… DOI 10.21873/anticanres.11001 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.